Surveillance of Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccines in the Vaccine Adverse Event Reporting System—United States, July 1, 2015–September 30, 2023
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Pedro L Moro und 20 weiteren Autor:innen. Beteiligte Einrichtung: Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Diphtheria-Tetanus-acellular Pertussis Vaccines. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess the safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in pregnant women in the United States using data from the Vaccine Adverse Event Reporting System (VAERS). Design, Setting We searched VAERS for reports of Tdap in pregnant women vaccinated during July 2015 through September 2023. We reviewed reports and available medical records for pregnancy and non‐pregnancy specific adverse events (AEs) in Tdap recipients. Reporting rates were estimated for reports of preterm birth, hypertensive disorders of pregnancy (HDP), and stillbirths and compared to published background rates for these conditions.
Results
VAERS received a total of 654 reports after Tdap vaccine in pregnancy and 137 (20.9%) were serious; no maternal or infant deaths were reported. The most common pregnancy specific conditions reported were preterm birth (45, 6.9%), hypertensive disorders of pregnancy (40, 6.1%), and stillbirth (18, 2.8%). Two reports of verified Guillain‐Barré Syndrome (GBS) were reported. The most common non‐pregnancy specific conditions reported were pain (120, 18.3%), nausea (93, 14.2%), and fever (87, 13.3%). Reporting rates for preterm birth, HDP, and stillbirths were below background rates for these conditions.
Conclusion
Most reports were non‐serious and the most common AEs were similar to those observed in pre‐ and post‐licensure studies. No new or unexpected AE was identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
ORCID-Profile: Pedro L Moro
Zitieren
APA
Moro, P. L., Romanson, B., Getahun, A., Strid, P., Zhang, B., Marquez, P., Ennulat, C., Brown, H., Sharkey, M., Hall, T., Jagdeo, P., Stibbe, C., Domville, J., Chambless, J., Woody, G., Pate, B., Shashi, S., Purgatorio, R., Sheikh, F., …, & Stroud, E. (2026). Surveillance of Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccines in the Vaccine Adverse Event Reporting System—United States, July 1, 2015–September 30, 2023. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70355
Vancouver
Moro PL, Romanson B, Getahun A, Strid P, Zhang B, Marquez P, et al. Surveillance of Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccines in the Vaccine Adverse Event Reporting System—United States, July 1, 2015–September 30, 2023. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70355
BibTeX
@article{Moro2026,
author = {Moro, Pedro L and Romanson, Brittney and Getahun, Aynalem and Strid, Penelope and Zhang, Bicheng and Marquez, Paige and Ennulat, Carol and Brown, Hannah and Sharkey, Martha and Hall, Traci and Jagdeo, Pavita and Stibbe, Caitlin and Domville, Jennifer and Chambless, Jenna and Woody, Gina and Pate, Brooke and Shashi, Sharma and Purgatorio, Rachel and Sheikh, Fatima and Zielke, Katherine and Stroud, Erin},
title = {Surveillance of Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccines in the Vaccine Adverse Event Reporting System—United States, July 1, 2015–September 30, 2023},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70355}
}
EUVIMED